Literature DB >> 954844

Discriminative pentobarbital stimulus in rats immediately after intravenous administration.

E C Krimmer, H Barry.   

Abstract

Rats with chronically implanted venous cannulas were trained to make differential active or passive shock-avoidance responses in a 2-compartment box at 15 sec after i.v. adminstration of pentobarbital (5 mg/kg) or saline. The discriminative pentobarbital stimulus persisted for several min after adminstration. The pentobarbital response also was elicited in tests at 15 sec after i.v. injection of chlordiazepoxide (2.5 and 5 mg/kg) or alcohol (500 mg/kg). Subsequent training at 10 min after i.p. injection of pentobarbital (10 mg/kg), followed by tests after i.p. administration of other drugs, indicated that the discriminative drug stimulus is qualitatively similar with this different route and time interval. A general preference for the passive over the active response developed only in the second stage of training, during i.p. injections.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 954844     DOI: 10.1016/0014-2999(76)90335-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

Review 1.  Early preclinical studies of discriminable sedative and hallucinogenic drug effects.

Authors:  Herbert Barry; James B Appel
Journal:  Psychopharmacology (Berl)       Date:  2008-08-20       Impact factor: 4.530

2.  A method to shorten the training phase of drug discrimination.

Authors:  C M Harris; D M Wood; H Lal; M W Emmett-Oglesby
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Discriminative stimulus properties of intravenous morphine in the rat.

Authors:  L G Frey; J C Winter
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530

4.  Discriminative, disinhibitory, and depressant effects of several anticonvulsants.

Authors:  E C Krimmer; H Barry; J D Alvin
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.